TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

The article provides strategies for each zodiac sign to combat negative thoughts. From engaging in physical activities and ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

Timely receipt of guideline-concordant care can improve survival and may help mitigate racial and ethnic disparities in survival among patients with inflammatory breast cancer, researchers wrote.

Only 45.5% of patients completed guideline-concordant surveillance within 30 months after treatment for high-grade cervical ...

Evercore ISI initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $30 price target The firm sees lead asset, ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell ...

A new study published in the journal of Research and Reports in Urology showed that lesion size was a crucial predictor of ...